Evidence map›Paper›PMID 24384537›Full record

ArticleHuman vaccines & immunotherapeutics2014

Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.

Maria Grazia Pascucci, Valentina Di Gregori, Gabriella Frasca, Paola Rucci, Alba Carola Finarelli, Laura Moschella, Bianca Maria Borrini, Francesca Cavrini, Giovanna Liguori, Vittorio Sambri and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Impact and effectiveness of meningococcal vaccines: a review.Revista panamericana de salud publica = Pan American journal of public health · 2017
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Maria Grazia PascucciRegional Health Authority; Bologna, Italy.
Valentina Di GregoriDepartment of Biomedical and Neuromotor Sciences; University of Bologna; Bologna, Italy.
Gabriella FrascaRegional Health Authority; Bologna, Italy.
Paola RucciDepartment of Biomedical and Neuromotor Sciences; University of Bologna; Bologna, Italy.
Alba Carola FinarelliRegional Health Authority; Bologna, Italy.
Laura MoschellaRegional Health Authority; Bologna, Italy.
Bianca Maria BorriniRegional Health Authority; Bologna, Italy.
Francesca CavriniUnit of Clinical Microbiology; S. Orsola-Malpighi University Hospital; Bologna, Italy.
Giovanna LiguoriUnit of Clinical Microbiology; S. Orsola-Malpighi University Hospital; Bologna, Italy.
Vittorio SambriUnit of Clinical Microbiology; S. Orsola-Malpighi University Hospital; Bologna, Italy; Unit of Clinical Microbiology; Greater Romagna Laboratory; Pievesestina, Cesena, Italy.
Paolo BonanniDepartment of Health Sciences; University of Florence; Florence, Italy.
Maria Pia FantiniDepartment of Biomedical and Neuromotor Sciences; University of Bologna; Bologna, Italy.
Regional Health · USUniversity of Bologna · ITPoliclinico S.Orsola-Malpighi · ITAzienda-Unita' Sanitaria Locale Di Cesena · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of reported meningococcal disease in Italy is among the lowest in Europe. The trend of the disease was increasing up to 2005 and then declined after the gradual introduction of a universal Men C vaccination program in 17/21 Italian regions. Since 2006, in Emilia-Romagna region vaccination against Neisseria meningitidis serogroup C was actively offered free of charge in a single dose to the age groups 12-15 months and 14-15 years, in addition to people with defined epidemiological risk. Our aim was to measure the impact of vaccination on the incidence of meningococcal disease caused by different serogroups among the population of Emilia Romagna Region, Northern Italy (approximately 4.5 million inhabitants) subdivided by age. Using surveillance data, we computed the incidence rates of Neisseria meninigitidis related invasive disease per 100.000 inhabitants for the years 2000 to 2012. In addition, the percentage change in incidence and the mortality rates were calculated. Results indicate a 70.1% decrease in the incidence of meningococcus C-related invasive disease after the introduction of MenC universal vaccination. No case of serogroup C related infection was observed since 2006 in children aged 1-4 years. These findings suggest that the single-dose vaccination strategy against serogroup C N.meningitidis targeted to the age groups 12-15 months and 14-15 years was effective in the Emilia-Romagna population. However, the occurrence of two cases of meningiditis in a 5-month child and in a 9-years child suggests caution and careful consideration in surveillance for the next years.

Indexed as

AdolescentAdultChildChild, PreschoolFemaleHumansIncidenceInfantItalyMaleMeningococcal InfectionsMeningococcal VaccinesMiddle AgedNeisseria meningitidis, Serogroup CSurvival AnalysisTreatment OutcomeMeningococcal Vaccinesserogroup C meningococcal conjugate vaccinemeningococcal diseaseserogroupssurveillancevaccination campaignvaccination coveragevaccination strategies

Identifiers

PMID24384537
PMCPMC4130270
OpenAlexW2088994228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.